Lakefront Biotherapeutics | GLPG - Debt


Lakefront Biotherapeutics reported EUR6.44M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
argenx SE USD 47.16M 4.01M Dec/2025
AstraZeneca USD 32.24B 1.68B Jun/2026
Biogen USD 8.09B 1.53B Jun/2026
Genmab DKK 5.35B 5.2B Mar/2026
Gilead Sciences USD 22.17B 2.76B Mar/2026
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
GRIFOLS EUR 8.52B 1.15B Jun/2026
Hikma Pharmaceutical USD 1.6B 46M Dec/2025
Incyte USD 38.27M 1.16M Jun/2026
Merck EUR 12.04B 86M Mar/2026
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Novartis USD 49.01B 2.02B Jun/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sanofi EUR 23.58B 3.56B Jun/2026
UCB EUR 3.03B 12M Dec/2024
Vertex Pharmaceuticals USD 1.98B 8.9M Jun/2026